DE60325261D1 - Behandlungsmethoden während eingriffen in das gefässsystem - Google Patents

Behandlungsmethoden während eingriffen in das gefässsystem

Info

Publication number
DE60325261D1
DE60325261D1 DE60325261T DE60325261T DE60325261D1 DE 60325261 D1 DE60325261 D1 DE 60325261D1 DE 60325261 T DE60325261 T DE 60325261T DE 60325261 T DE60325261 T DE 60325261T DE 60325261 D1 DE60325261 D1 DE 60325261D1
Authority
DE
Germany
Prior art keywords
intervention
vascular
treatment methods
vessel system
rar
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60325261T
Other languages
English (en)
Inventor
Roshantha A Chandraratna
Yang-Dar Yuan
Tuong P Dang
Sheng Z Loh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allergan Inc
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Application granted granted Critical
Publication of DE60325261D1 publication Critical patent/DE60325261D1/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/382—Heterocyclic compounds having sulfur as a ring hetero atom having six-membered rings, e.g. thioxanthenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
DE60325261T 2002-10-22 2003-10-21 Behandlungsmethoden während eingriffen in das gefässsystem Expired - Fee Related DE60325261D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/278,770 US7105566B2 (en) 2002-10-22 2002-10-22 Methods of treatment during vascular procedures
PCT/US2003/033558 WO2004037243A2 (en) 2002-10-22 2003-10-21 Methods of treatment during vascular procedures

Publications (1)

Publication Number Publication Date
DE60325261D1 true DE60325261D1 (de) 2009-01-22

Family

ID=32093435

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60325261T Expired - Fee Related DE60325261D1 (de) 2002-10-22 2003-10-21 Behandlungsmethoden während eingriffen in das gefässsystem

Country Status (6)

Country Link
US (1) US7105566B2 (de)
EP (1) EP1558235B1 (de)
AT (1) ATE416764T1 (de)
AU (1) AU2003301673A1 (de)
DE (1) DE60325261D1 (de)
WO (1) WO2004037243A2 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005054468A1 (ja) * 2003-12-01 2005-06-16 Reverse Proteomics Research Institute Co., Ltd. 抗糖尿病剤の標的タンパク質及び対応する新規抗糖尿病剤「インスフル」
JP2009510114A (ja) 2005-09-30 2009-03-12 ビテ ファーマシューティカルズ， インコーポレイテッド 特定のｒｘｒアゴニストによる癌治療
TR201819157T4 (tr) * 2006-05-16 2019-01-21 Io Therapeutics Llc Kemoterapi Ve Veya Radyasyon Terapisinin Yan Etkilerinin Tedavisinde Kullanıma Yönelik Rar Antagonisti Veya Ters Agonisti
GB0915196D0 (en) * 2009-09-01 2009-10-07 King S College London Therapeutic compounds and their use
CN104114171A (zh) 2011-12-13 2014-10-22 Io治疗公司 使用rxr激动剂的自身免疫紊乱的治疗
CN108289958A (zh) 2015-10-31 2018-07-17 Io治疗公司 使用rxr激动剂和甲状腺激素的组合治疗神经系统紊乱
AU2016396658B2 (en) 2016-03-10 2019-02-21 Io Therapeutics, Inc. Treatment of autoimmune diseases with combinations of RXR agonists and thyroid hormones
MX2018010863A (es) 2016-03-10 2019-01-10 Io Therapeutics Inc Tratamiento contra trastornos musculares con combinaciones de agonistas rxr y hormonas tiroideas.
US11517549B2 (en) 2017-09-20 2022-12-06 Io Therapeutics, Inc. Treatment of disease with esters of selective RXR agonists
US10966950B2 (en) 2019-06-11 2021-04-06 Io Therapeutics, Inc. Use of an RXR agonist in treating HER2+ cancers
US20230357175A1 (en) * 2019-12-19 2023-11-09 Orphagen Pharmaceuticals, Inc. Rar-alpha compounds for inflammatory disease and male contraception
WO2023108012A1 (en) 2021-12-07 2023-06-15 Io Therapeutics, Inc. Use of an rxr agonist and taxanes in treating her2+ cancers

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69309670T2 (de) 1992-12-28 1997-11-20 Eisai Co Ltd Heterocyclische carbonsäure-derivate, die an rar rezeptoren binden können
US5648514A (en) * 1994-12-29 1997-07-15 Allergan Substituted acetylenes having retinoid-like biological activity
US6008204A (en) * 1995-09-01 1999-12-28 Allergan Sales, Inc. Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities
US5776699A (en) * 1995-09-01 1998-07-07 Allergan, Inc. Method of identifying negative hormone and/or antagonist activities
US5958954A (en) 1995-09-01 1999-09-28 Allergan Sales, Inc. Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities
US6218128B1 (en) * 1997-09-12 2001-04-17 Allergan Sales, Inc. Methods of identifying compounds having nuclear receptor negative hormone and/or antagonist activities
PT873295E (pt) * 1995-10-06 2003-08-29 Ligand Pharm Inc Moduladores de rxr selectivos para dimeros para a sua utilizacao
US5877207A (en) * 1996-03-11 1999-03-02 Allergan Sales, Inc. Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities
FR2753627B1 (fr) * 1996-09-20 2003-02-21 Galderma Rech Dermatologique Utilisation des inhibiteurs de l'activite de l'acide retinoique pour favoriser la cicatrisation
US6037488A (en) * 1997-04-19 2000-03-14 Allergan Sales, Inc. Trisubstituted phenyl derivatives having retinoid agonist, antagonist or inverse agonist type biological activity
US5919970A (en) * 1997-04-24 1999-07-06 Allergan Sales, Inc. Substituted diaryl or diheteroaryl methanes, ethers and amines having retinoid agonist, antagonist or inverse agonist type biological activity
DE69835441T2 (de) * 1997-11-12 2007-08-02 F. Hoffmann-La Roche Ag Behandlung von t-helfer zell typ 2 vermittelten immunkrankheiten mit retinoid antagonisten
US6521641B1 (en) * 1998-10-08 2003-02-18 Allergan, Inc. Male anti-fertility agents
AU2001290816A1 (en) 2000-09-13 2002-03-26 Bristol-Myers Squibb Company Retinoic acid receptor antagonists as promoters of angiogenesis
US20020193403A1 (en) * 2001-05-03 2002-12-19 Allergan Sales, Inc. Methods of treating hyperlipidemia
WO2003024473A2 (en) * 2001-09-17 2003-03-27 The University Of Western Ontario Retinoid receptor pan-antagonists for stimulating chondrogenesis

Also Published As

Publication number Publication date
EP1558235B1 (de) 2008-12-10
WO2004037243A2 (en) 2004-05-06
AU2003301673A1 (en) 2004-05-13
ATE416764T1 (de) 2008-12-15
EP1558235A2 (de) 2005-08-03
WO2004037243A3 (en) 2004-09-30
US20040077710A1 (en) 2004-04-22
US7105566B2 (en) 2006-09-12

Similar Documents

Publication Publication Date Title
Bergan et al. Surgical and endovascular treatment of lower extremity venous insufficiency
Schaden et al. Shock wave therapy for acute and chronic soft tissue wounds: a feasibility study
DE60312309D1 (de) Verwendung von botulinum toxin zur behandlung von herz- und kreislaufskrankheiten
Kalra et al. Surgical treatment of venous ulcers: role of subfascial endoscopic perforator vein ligation
WO2006037088A3 (en) Method and device for extravascular intervention
ATE506019T1 (de) Kontrollierbare vorrichtung und kit zur behandlung von störungen des herzrhythmus- reguliersystems
DE60325261D1 (de) Behandlungsmethoden während eingriffen in das gefässsystem
ATE524070T1 (de) Verfahren zur verwendung von aus fettgewebe stammenden zellen bei der behandlung von herz- kreislauf-leiden
BR0212252A (pt) Métodos para reduzir a hipertensão e a insuficiência cardìaca em um mamìfero
DE60030889D1 (de) Verwendung von egfr tyrosine kinase hemmern zur behandlung von brustkrebs
SG146666A1 (en) Methods of using regenerative cells in the treatment of peripheral vascular disease and related disorders
WO2005011787A3 (en) Apparatus and method for treating intravascular disease
DE602005026724D1 (de) Verfahren zur verwendung von aus fettgewebe stammenden zellen bei der behandlung von herz-kreislauf-leiden
NO20060498L (no) Metode for a promotere benvekst
WO2006014159A3 (en) Methods of using regenerative cells in the treatment of musculoskeletal disorders
ATE422357T1 (de) Verwendung von allopurinol zur behandlung von bluthochdruck
DE60218843D1 (de) Verfahren zur identifizierung von mitteln zur behandlung von diabetes
Kurz et al. Activation of healing and reduction of pain by single‐use automated microcurrent electrical stimulation therapy in patients with hard‐to‐heal wounds
NO20021410L (no) Forebygging og behandling av blodkoagulasjons-relaterte sykdommer
WO2003082263A8 (en) Sulfamic acids as inhibitors of human cytoplasmic protein tyrosine phosphatases
RU117284U1 (ru) Венэкстрактор
El Bakkali et al. Autonomic dysregulation in primary hypertension
DE602004028876D1 (de) Verfahren zur verwendung regenerativer zellen bei der behandlung von nierenkrankheiten und störungen
ATE306278T1 (de) Behandlung von knochenleiden mit adrenomedullin
Sabry et al. Cross-leg flaps: Case series, review, and proposed classification

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee